Center for Biosimilars News
4 FOLLOWERS
The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We'll discuss the current landscape for advanced health care management-reviewing emerging treatment paradigms, approaches, and considerations all by authoritative industry voices.
Center for Biosimilars News
2d ago
Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD ..read more
Center for Biosimilars News
3d ago
Here are the top 5 biosimilar articles for the week of September 2, 2024 ..read more
Center for Biosimilars News
4d ago
Patients with rheumatoid arthritis who switched from the etanercept originator to a biosimilar exhibited similar disease activity and drug persistence compared with those who remained on the originator, indicating that nonmedical switching does not negatively impact treatment outcomes ..read more
Center for Biosimilars News
5d ago
A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential ..read more
Center for Biosimilars News
5d ago
Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings ..read more
Center for Biosimilars News
5d ago
Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and the evolving role of pharmacy benefit managers in the market ..read more
Center for Biosimilars News
1w ago
On this episode of Not So Different, the end of the second quarter brings with it expense reports, new biosimilar business deals, and insights into how federal policy impacts biosimilar company pursuits ..read more
Center for Biosimilars News
1w ago
Here are the top 5 biosimilar articles for the week of August 26, 2024 ..read more
Center for Biosimilars News
1w ago
The 2023 European Alliance of Associations for Rheumatology (EULAR) recommendations for psoriatic arthritis (PsA) provide an evidence-based treatment strategy, prioritizing conventional and biological disease-modifying antirheumatic drugs, including biosimilars, tailored to disease manifestations, with an emphasis on safety, cost-effectiveness, and patient-centered care ..read more
Center for Biosimilars News
1w ago
Sandoz’ earnings report for the first half of 2024 revealed 29% growth in biosimilar revenue, as well as a 7% increase in net sales, showcasing the value of biosimilars for biopharmaceutical manufacturers ..read more